Overview

• Lilly launched TuneLab with 18 models, including 12 for small‑molecule property prediction and six for antibody developability.
• The platform’s models are trained on proprietary research data accumulated over decades at a cost reported to exceed $1 billion.
• Selected biotech partners receive access in exchange for contributing experimental data that will be used to further train and improve the models.
• Circle Pharma will use TuneLab to strengthen its MXMO macrocycle platform and advance oncology programs, including the phase 1 candidate CID‑078.
• insitro will build new models for TuneLab to support small‑molecule discovery, with additional model releases planned, including analysis of in vivo data.